On August 5, Liquidia Technologies Inc rose 5.41% in regular trading, trading at $88.475 USD/share, with Turnover of $35.17 million.
Within the Pharmacy sector where Liquidia Technologies Inc belongs, the overall sector showed mixed performance. Among individual stocks, Eli Lilly up 0.41%, Pfizer up 2.14%, AstraZeneca PLC down 0.1%, Johnson & Johnson down 0.73%, Merck up 1.0%.
Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing products for unmet patient needs, with current emphasis on pulmonary arterial hypertension treatment. Its lead product YUTREPIA generated approximately $130 million in net product sales in Q1, with EPS of $0.52. The company is scheduled to report next quarterly results on August 12, with market consensus EPS estimate of $0.70.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)